Literature DB >> 17261470

Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension.

Toshiaki Suguro1, Takuya Watanabe, Yoshiyuki Ban, Syuusuke Kodate, Asako Misaki, Tsutomu Hirano, Akira Miyazaki, Mitsuru Adachi.   

Abstract

BACKGROUND: Circulating blood levels of human urotensin II (U-II), the most potent vasoconstrictor peptide identified to date, are increased in patients with essential hypertension. Our previous studies showed that U-II accelerates human macrophage foam cell formation and vascular smooth muscle cell proliferation, suggesting development of atherosclerotic plaque. In this study, we demonstrated a correlation between plasma U-II level and progression of atherosclerosis in hypertensive patients.
METHODS: The intima-media thickness (IMT) and plaque score in the carotid artery, blood pressure (BP), plasma levels of U-II, and atherosclerotic parameters were determined in 50 hypertensive patients and 31 normotensive controls.
RESULTS: Plasma U-II level, maximum IMT, plaque score, systolic BP, and homeostasis model assessment for insulin resistance (HOMA-IR) were significantly greater in hypertensive patients than normotensive controls. Age, gender, body mass index, and serum levels of high-sensitive C-reactive protein (CRP), HDL and LDL cholesterols, small dense LDL, triglycerides, lipoprotein(a), insulin, and fasting plasma glucose level were not significantly different between the two groups. In all subjects, plasma U-II level showed significant positive correlations with systolic BP, maximum IMT, plaque score, and HOMA-IR. Multiple logistic regression analysis indicated that the contribution of plasma U-II levels to carotid plaque formation (plaque score >/=1.1) was significantly still greater with a 60% increase than those of established risk factors, such as age, systolic BP, high-sensitive CRP, small dense LDL, and HOMA-IR.
CONCLUSIONS: Our results suggest that increased levels of U-II may play a crucial role in the development of carotid atherosclerosis in hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17261470     DOI: 10.1016/j.amjhyper.2006.08.001

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  15 in total

1.  Renal impairment, hypertension and plasma urotensin II.

Authors:  Ari Mosenkis; Radhakrishna R Kallem; Theodore M Danoff; Nambi Aiyar; Jonathan Bazeley; Raymond R Townsend
Journal:  Nephrol Dial Transplant       Date:  2010-07-09       Impact factor: 5.992

2.  Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?

Authors:  M Demirpence; A Guler; H Yilmaz; A Sayin; Y Pekcevik; H Turkon; A Colak; E M Ari; B Aslanipour; G U Kocabas; M Calan
Journal:  J Endocrinol Invest       Date:  2018-05-26       Impact factor: 4.256

3.  Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype.

Authors:  Damien Gruson; Michel F Rousseau; Jean-Marie Ketelslegers; Michel P Hermans
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-08       Impact factor: 3.738

4.  Potential Clinical Implications of the Urotensin II Receptor Antagonists.

Authors:  Philip Tsoukas; Emilie Kane; Adel Giaid
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810

5.  Association between human urotensin II and essential hypertension--a 1:1 matched case-control study.

Authors:  Hao Peng; Mingzhi Zhang; Xiaoqin Cai; Jennifer Olofindayo; Anna Tan; Yonghong Zhang
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

Review 6.  Urotensin II in cardiovascular regulation.

Authors:  Fraser D Russell
Journal:  Vasc Health Risk Manag       Date:  2008

7.  Urotensin II promotes atherosclerosis in cholesterol-fed rabbits.

Authors:  Yafeng Li; Sihai Zhao; Yanli Wang; Yulong Chen; Yan Lin; Ninghong Zhu; Huadong Zheng; Min Wu; Daxing Cheng; Yandong Li; Liang Bai; Jianglin Fan; Enqi Liu
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

8.  Inhibitory Effect of an Urotensin II Receptor Antagonist on Proinflammatory Activation Induced by Urotensin II in Human Vascular Endothelial Cells.

Authors:  Sung Lyea Park; Bo Kyung Lee; Young-Ae Kim; Byung Ho Lee; Yi-Sook Jung
Journal:  Biomol Ther (Seoul)       Date:  2013-07-30       Impact factor: 4.634

9.  The urotensin system is up-regulated in the pre-hypertensive spontaneously hypertensive rat.

Authors:  Ellen J Forty; Nick Ashton
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

10.  Autocrine Human Urotensin II Enhances Macrophage-Derived Foam Cell Formation in Transgenic Rabbits.

Authors:  Sihai Zhao; Yafeng Li; Shoucui Gao; Xiaojing Wang; Lijing Sun; Daxing Cheng; Liang Bai; Hua Guan; Rong Wang; Jianglin Fan; Enqi Liu
Journal:  Biomed Res Int       Date:  2015-11-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.